key: cord-0714570-z3c8e7wy
authors: Ahmad, Faran; Ahmed, Arslan; Rajendraprasad, Sanu S.; Loranger, Austin; Gupta, Sonia; Velagapudi, Manasa; Vivekanandan, Renuga; Nahas, Joseph A.; Plambeck, Robert; Moore, Douglas
title: Multisystem Inflammatory Syndrome in Adults: A Rare Sequela of SARS-CoV-2 Infection
date: 2021-05-24
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.050
sha: 07a62114a9b47d815aede3a229e09e67abd47c0c
doc_id: 714570
cord_uid: z3c8e7wy

The multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) got initial reports regarding the patients who had delayed and multisystem involvement of the disease with clinical course resembling the multisystem inflammatory syndrome in children (MIS-C). We share a case of MIS-A, where the patient presented three weeks after the initial COVID19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on the treatment modalities and clinical predictors.

2  Immunomodulatory therapeutics can have a pivotal role in the management of MIS-A.

The multisystem inflammatory syndrome in adults (MIS-A) came to attention back in June 2020, when the United States Center for Disease Control and Prevention (CDC) got initial reports regarding the patients who had delayed and multisystem involvement of the disease with clinical course resembling the multisystem inflammatory syndrome in children (MIS-C). We share a case of MIS-A, where the patient presented three weeks after the initial COVID19 exposure. His clinical course was consistent with the working definition of MIS-A as specified by CDC. Aggressive supportive care in the intensive care unit, utilization of advanced heart failure devices, and immunomodulatory therapeutics (high dose steroids, anakinra, intravenous immunoglobulin) led to clinical recovery. Management of MIS-A is a topic of ongoing research and needs more studies to elaborate on the treatment modalities and clinical predictors. 

A 26-year-old Caucasian male nonsmoker presented to the emergency room with 5 days of diffuse abdominal pain, constant in nature, described as 5 out of 10 in intensity, and associated with fever, nausea, loose stool, and decreased urine output. He additionally noted a rash on his hands and feet that started 3 days prior to the presentation. His roommate had COVID-19 three weeks ago. The patient self-quarantined for 10 days and his reverse transcriptasepolymerase chain reaction (RT-PCR) test for SARS-CoV-2 was reported negative at the end of quarantine. He was afebrile, had a blood pressure of 98/48 mmHg, respiratory rate of 35/minute, and 94% saturation on room air. On chest auscultation, the lungs were clear bilaterally. His abdomen was soft, non-distended with generalized tenderness to deep palpation. Initial abnormal laboratory studies included BUN 38 mg/dl, creatinine 4.66 mg/dl, CRP 246 mg/L, ferritin 1657 ng/ml, LDH 236 u/L, procalcitonin 105.12 ng/ml, D-dimer 2.03, J o u r n a l P r e -p r o o f venous lactate: 9.7 mg/dl and WBC count of 21700/uL with 71% bands (Table 1) . Now he tested positive for SARS-CoV-2 by nasopharyngeal PCR test and the SARS-CoV-2 antibody reported positive as well. A duplex venous scan of the lower extremities revealed an acute left peroneal deep vein thrombosis. His initial chest X-ray revealed mild peribronchial thickening and a noncontrast CT scan of the abdomen illustrated lymphadenopathy in the ileocolic mesentery and bilateral peri-nephric edema. Over the course of the next 12 hours, his mean arterial pressure dropped to less than 60 mmHg, requiring initiation of vasopressor support. A transthoracic echocardiogram (TTE) revealed a new markedly reduced left ventricular ejection fraction (LVEF) of 15-20% and severe right ventricular dysfunction. He eventually required endotracheal intubation for rapidly progressive cardiogenic shock along with the commencement of mechanical ventilation prior to requiring Impella placement and continuous renal replacement therapy (CRRT). He received intravenous immunoglobulin (IVIG) at a dose of 1 mg/kg once followed by IV methyl-prednisone 250mg every 6 hours, subcutaneous anakinra 100mg every 6 hours, and aspirin 325 mg daily. Anakinra dose was tapered over the course of 2 weeks. After 10 days in the intensive care unit, his LVEF recovered to 60%. His presentation and clinical course were consistent with the working definition of MIS-A.

According to the CDC, the working case definition for a typical MIS-A presentation includes the presence of a severe illness requiring hospitalization in persons aged 21 or greater, positive test results for recent SARS-CoV-2 infection (PCR, antigen, or antibody), severe dysfunction of one or more extra-pulmonary organ systems as well as markedly elevated acute inflammatory J o u r n a l P r e -p r o o f markers, all in the absence of severe respiratory illness to exclude the subset of the patients in which organ dysfunction might be the result of tissue hypoxia (Morris et al., 2020) .

In October 2020, the CDC published an initial review of 27 cases with a clinical course consistent with MIS-A (Chau et al., 2020; Magro et al., 2020; Oxley et al., 2020) . Those cases had heterogeneous involvement of cardiac, gastrointestinal, dermatologic, and neurologic symptoms without severe respiratory system involvement at presentation. The first reported case series of CDC Morbidity and mortality weekly report (MMWR) included 11 MIS-A patients based on the data collected from March to August of 2020, seven of which had a cardiogenic shock on presentation (Morris et al., 2020) . Similarly, a recent review of 51 cases with MIS-A highlighted that cardiovascular involvement has been the most frequently reported finding (82.4%) followed by gastrointestinal manifestations(72.5%) (Bastug et al., 2021) . Importantly, in MIS-A, initial COVID-19 infection can be asymptomatic as well (Morris et al., 2020) . This has been further illustrated in the case-based review of 51 MIS-A cases, where only 14 patients had previous symptomatic COVID-19 illness while in the remaining cases the initial COVID-19 infection was either asymptomatic or no data was available (Bastug et al., 2021) . Elevated CRP, neutrophils count, ESR, and fibrinogen have been reported in more than 75% of MIS cases in adolescents (Feldstein et al., 2020) .

The proposed COVID-19 infectious process includes three progressive clinical phases (Siddiqi and Mehra, 2020) . MIS-A is proposed to be a rather post-infectious phase driven by dysregulated immune complex activation causing direct endothelial damage and associated thrombo-inflammation (Morris et al., 2020) . Notably, as compared to severe COVID-19, patients with MIS are more likely to have cardio-respiratory involvement (56.0% vs 8.8%) and cardiovascular without respiratory involvement (10.6% vs 2.9%) on presentation (Feldstein et al., 2021) .

It should be noted that while serology consistent with prior COVID-19 infection is required to fulfill the case definition of MIS-A, it has minimal prognostic or diagnostic role due to various limiting factors, including persistent PCR detection of non-replicable SARS-CoV-2 RNA and persistent antibody positivity due to remote previous exposure (Bastug et al., 2021; Hékimian et al., 2021) . Recently, the American College of Rheumatology has published its initial recommendations for the management of hyper-immune response in the post-infectious phase of COVID-19, particularly focusing on MIS-C and the role of immunomodulatory therapies i.e. intravenous immunoglobulin (IVIG) and anakinra (Henderson et al., 2020) .

inflammation (Lo and Newburger, 2018) . Based on its mechanism of action, IVIG is considered a first-tier therapy, and steroids can be used as adjunctive therapy in cases of distributive shock.

The proposed starting dose of IVIG is 2gm/kg (Jiang et al., 2020) .

J o u r n a l P r e -p r o o f management of various auto-immune conditions. It has shown to have a quick onset of action, short half-life (4 hr), and a large therapeutic window. Moreover, anakinra is rather preferred over tocilizumab given its safety profile and lesser myelosuppressive and hepatotoxic effect (Mehta et al., 2020) . Interestingly, there is no randomized controlled trial to elaborate on the role of anakinra in adults with MIS-A so far. Our case shows that following a similar protocol as done in children with MIS-C, anakinra is likely to be effective. The American College of Rheumatology has mentioned in its recommendations regarding MIS-A that anakinra can be considered as an additional therapy in patients refractory to IVIG and glucocorticoids (Siddiqi and Mehra, 2020) . The proposed starting dose is greater than 4 mg/kg/day IV, with the eventual plan of tapering the dose based on clinical recovery and resolution of the markers of inflammation.

Overall, we are still in the early stages of understanding MIS-A. More research is needed to further delineate diagnostic and prognostic markers of MIS-A as well as elaborate on disease management in critically ill patients. There was no financial support or funding support involved in the preparation of this manuscript Ethical Approval:

Not required. The individual case report submission is exempt from the Institutional Review Board approval. 

Multiple system inflammatory syndrome associated with SARS-CoV-2 infection in an adult and an adolescent

Cardiogenic Shock and Hyperinflammatory Syndrome in Young Males With COVID-19

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Role of intravenous immunoglobulin in the treatment of Kawasaki disease

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

COVID-19 illness in native and immunosuppressed states: A clinicaltherapeutic staging proposal

SARS-COV-2 serology, PCR and other abnormal laboratory results for current admission

All authors declare:•No financial relationships with any organizations that might have an interest in the submitted work.• No other relationships or activities that could appear to have influenced the submitted work.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.